Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa L Johnson

Showing results (11-20 of 94) with videos related to

Pageof 10
Sort By:
Future Oncology (London, England)|January 21, 2021
Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet needSiwen Hu-Lieskovan, Gabriel G Malouf, Ira Jacobs, et al.
The Oncologist|May 2, 2023
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesMelissa L Johnson, Manish R Patel, Raid Aljumaily, et al.
Clinical Lung Cancer|October 6, 2012
Importance and relevance of pulmonary symptoms among patients receiving second- and third-line treatment for advanced non-small-cell lung cancer: support for the content validity of the 4-item Pulmonary Symptom IndexSusan Magasi, Rajiv Mallick, Karen Kaiser, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2012
Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancersAnna M Varghese, Camelia S Sima, Jamie E Chaft, et al.
Targeted Oncology|November 10, 2025
Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung CancerMelissa L Johnson, Shaker R Dakhil, J Thaddeus Beck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2026
The SOS1 inhibitor BI 1701963 as monotherapy or in combination with trametinib in patients with KRAS mutation-positive solid tumorsPasi A Jänne, Melissa L Johnson, Jin Li, et al.
Cancer|July 20, 2012
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomasMelissa L Johnson, Camelia S Sima, Jamie Chaft, et al.
Clinical Lung Cancer|March 8, 2023
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II StudyMelissa L Johnson, James Strauss, Manish R Patel, et al.
Targeted Oncology|October 25, 2021
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of AdministrationSiwen Hu-Lieskovan, Fadi Braiteh, Juneko E Grilley-Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2015
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice GuidelineAndrea Bezjak, Sarah Temin, Gregg Franklin, et al.
Pageof 10

Showing results (11-20 of 94) with videos related to

Sort By:
Pageof 10
Future Oncology (London, England)|January 21, 2021
Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet needSiwen Hu-Lieskovan, Gabriel G Malouf, Ira Jacobs, et al.
The Oncologist|May 2, 2023
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesMelissa L Johnson, Manish R Patel, Raid Aljumaily, et al.
Clinical Lung Cancer|October 6, 2012
Importance and relevance of pulmonary symptoms among patients receiving second- and third-line treatment for advanced non-small-cell lung cancer: support for the content validity of the 4-item Pulmonary Symptom IndexSusan Magasi, Rajiv Mallick, Karen Kaiser, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2012
Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancersAnna M Varghese, Camelia S Sima, Jamie E Chaft, et al.
Targeted Oncology|November 10, 2025
Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung CancerMelissa L Johnson, Shaker R Dakhil, J Thaddeus Beck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2026
The SOS1 inhibitor BI 1701963 as monotherapy or in combination with trametinib in patients with KRAS mutation-positive solid tumorsPasi A Jänne, Melissa L Johnson, Jin Li, et al.
Cancer|July 20, 2012
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomasMelissa L Johnson, Camelia S Sima, Jamie Chaft, et al.
Clinical Lung Cancer|March 8, 2023
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II StudyMelissa L Johnson, James Strauss, Manish R Patel, et al.
Targeted Oncology|October 25, 2021
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of AdministrationSiwen Hu-Lieskovan, Fadi Braiteh, Juneko E Grilley-Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2015
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice GuidelineAndrea Bezjak, Sarah Temin, Gregg Franklin, et al.
Pageof 10